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Abstract 
 Since the seminal work on spherical nucleic acids (SNAs) by Mirkin and co-workers in 
1996, substantial research investment has been devoted to gold nanoparticle (AuNP)-based 
biotechnology advancement. AuNPs have several unique attributes, making them ideal for a 
wide variety of applications ranging from medicinal diagnostics and cancer therapy to 
environmental and chemical sensing. First, AuNPs are known to exhibit high surface area-to- 
volume ratios leading to rapid reaction kinetics and enhanced drug and polymer loading 
capabilities. Additionally, gold nanoparticles offer a high degree of biocompatibility, 
controllable synthesis, and near covalent-strength interactions with thiolated molecules. 
Moreover, gold nanomaterials embody fascinating and unique optical properties derived from the 
interaction between surface electrons and electromagnetic radiation. By tuning the nanoparticle 
shape, size and ligand density, these optical properties can be altered, leading to an impressive 
diversity of technological and medicinal applications. 
Doxorubicin is an effective chemotherapeutic used to treat a variety of cancers including 
solid masses and leukemia. Clinically, its mechanism of action involves the intercalation of 
double-stranded DNA and the inhibition of important cellular replication enzymes. Typically, 
doxorubicin is administered in liposomal forms in order to mitigate the harsh cardiotoxicity 
associated with its use. Despite advances in this field, many side effects still exist and innovative 
delivery mechanisms remain highly desirable. Drug delivery studies employing doxorubicin 
often rely on the molecule’s fluorescent region for effective quantification, despite previously-
reported issues related to non-specific adsorption of the drug molecule to container surfaces. 
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Here, several research questions related to AuNPs and doxorubicin are addressed. First, 
the extent to which doxorubicin non-specifically adsorbs to plastic vessels in drug delivery 
studies is examined and a simple blocking technique using trace amounts of polyethylene glycol 
is reported and systematically characterized. Through the inclusion of trace amounts of 
polyethylene glycol in fluorescence measurement buffer, quantitative errors can be inhibited, 
ensuring accurate drug loading for downstream experimental application. Second, the chemical 
adsorption mechanism between doxorubicin and AuNPs is systematically studied. Traditionally, 
the interaction was believed to be dominated by an electrostatic attraction between the 
protonated moiety of the drug and the negatively-charged citrate-capping agent coating the 
nanoparticle surface. Here, that theory is challenged upon the proposal of a multifaceted 
adsorption process, whereby coordination and cation-π-based interactions between the drug and 
nanoparticle are dominant.  
The investigations described above help to advance the fields of nanotechnology and 
drug delivery by first providing a robust doxorubicin quantification method and second by 
providing insights into the chemical nature of doxorubicin-gold conjugates. Together, these 
discoveries may influence future drug delivery research studies that utilize both doxorubicin and 
gold nanomaterials. 
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Chapter 1 General Introduction 
1.1 Introduction 
Within the research field of nanotechnology, the feasible delivery of potent 
chemotherapeutics using nanomaterials has received a substantial amount of interest in 
recent years. Doxorubicin (DOX) is a frontline anthracycline chemotherapeutic used to 
treat a variety of cancers including lung, breast and ovarian forms (Duggan and Keating, 
2011; Green and Rose, 2006; Lv et al., 2014). Its effectiveness has stood the test of time, 
being discovered in the 1950’s, approved for clinical use by the Food and Drug 
Administration (FDA) over 30 years ago and still finding applicability in 
chemotherapeutic cocktails and research laboratories today (Judson et al.; Prados et al., 
2012).  
Of the nanomaterials currently being surveyed for utility in clinical drug delivery 
system development, gold nanoparticles have become ubiquitous. Since the seminal work 
of Mirkin and co-workers on spherical nucleic acid (SNA) development, numerous 
research groups have built expertise in using nano-sized gold spheres and rods to combat 
disease and fast track diagnostics (Akiyama et al., 2009; Mirkin et al., 1996; Williams, 
2013). This thesis contributes to advancing the field of nanotechnology by focusing on 
gold nanoparticle-based therapeutics and targeting platforms for use in the treatment of 
cancer.  
1.2 Nanotechnology 
Under the broad umbrella of biomedical research lies the field of nanotechnology 
and specifically within the context of cancer treatment, nanomedicine, where nanoscale 
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systems are developed and manipulated to kill cancer cells and tissues. Over the course of 
the past two decades, nanoparticle-related research has seen the development of several 
novel drug delivery system designs and continued future investment will undoubtedly 
help to fully realize the potential nanoscale applications have in medicine (Chen et al., 
2011). Nanomaterials are generally defined as those between 1-100 nm; however, drug 
delivery carriers and nanosensors are often larger in size (Liu et al., 2012; Rengan et al., 
2014).  
1.2.1 Gold Nanoparticles 
Gold nanoparticles (AuNP) are aqueous suspensions of nano-sized gold core 
particles that are extensively used in the field of nanotechnology research. Their ease and 
control of synthesis, optical properties, biocompatibility and high surface area to volume 
ratios make their use in biotechnology and drug delivery increasingly attractive. 
Traditional spherical AuNP are most commonly synthesized by the routine citrate-
reduction method popularized over 40 years ago, (Frens, 1973) where gold salt is boiled 
before the addition of citric acid solution. Upon citrate addition, the solution changes 
from a yellow color to wine red over the course of ~ 15-30 minutes, signifying the 
growth of nanometer-sized gold particles. By altering the concentrations of the reagents 
in the reaction, the size and concentration of the prepared nanoparticles can be tuned with 
precise control. Upon competition, the as-synthesized particles are capped by the 
negatively-charged citrate ions used to reduce the gold salt. These ions provide repulsive 
electrostatic stabilization of the nanoparticles in solution. Changes in the solution 
properties such as increasing ionic strength or varying pH will screen the negative 
charges on the surface of the particles and cause rapid and irreversible aggregation 
 3 
witnessed by wine red to blue color change and a shift in the optical absorbance of the 
nanoparticle solution. This instability, or aggregation, leads to the clumping of 
nanoparticles in solution, driven by van der Waals interactions between the dense cores 
of the nanoparticles.  
At the nanoscale, unique physical phenomena allow for the development of useful 
biomedical systems. For example, the ways in which surface electrons on gold 
nanoparticles of different shapes and morphologies interact with light to produce surface 
plasmon resonance (SPR) effects have formed the basis of commercialized disease-
diagnostic systems (Figure 1.1). Nano-sized delivery systems rely on the enhanced 
permeation and retention (EPR) effect (Figure 1.2) in vivo, whereby nanoconjugates <200 
nm in size are optimal for particle deposition from leaky vasculature into the tumor 
microenvironment (Kobayashi et al., 2014). Therefore, considerations such as size, 
stability and biocompatibility are of the utmost importance when designing nanoscale 
drug delivery systems and much effort is being spent designing optimal systems within 
the field today (Farokhzad and Langer, 2009).  
1.3 Cancer 
In broad terms, cancer is defined as the uncontrollable division and proliferation 
of cells within the body. Eventually these abnormal cells form masses known as tumors, 
which can lead to disturbances in organ function and death if left untreated. In reality, the 
disease is much more complicated than this general definition suggests. In 2000, Hanahan 
and Weinberg published their seminal work entitled, The Hallmarks of Cancer (Hanahan 
and Weinberg, 2000). The authors identify six landmark features to better explain the
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Figure 1.1 Near-infrared absorbing hollow gold nanoparticles (left) and commonly-used 13 nm-citrate-capped AuNP (right). TEM images found 
below respective nanomaterials with scale bars included. 
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intricacies associated with a disease encompassing over 200 varieties. In 2011, the 
authors updated their work in light of a decade of scientific advancement in the 
understanding and characterization of each of the six hallmarks: sustaining proliferative 
signaling, evading growth suppressors, activating invasion and metastasis, enabling 
replicative immortality, inducing angiogenesis and resisting cell death (Hanahan and 
Weinberg, 2011). The extent to which each of these hallmarks is propagated in the body 
correlates strongly with the overall success and progression of cancer. 
1.3.1 Theories of Origin 
One well-supported hypothesis describing the nature of the disease is known as 
the monoclonal theory of cancer origin. Under this theory, cancer is understood as the 
product of compounding mutations in a normal cell lineage which are referred to as 
clonal expansions (Weinberg, 2014). These mutations, being passed from one generation 
to the next, allow for increased fitness relative to non-mutated populations. After a 
specific number and combination of mutations is acquired, a malignant status is reached. 
Recent advances in cancer stem cell (CSC) theory have underscored the complexity 
associated with cancer origins (Kalluri and Weinberg, 2009). Research has shown that 
only a very low percentage of transplanted tumor cells are actually able to form tumors in 
a new host organism (Bonnet and Dick, 1997). These results provide evidence of the 
existence of tumorigenic CSCs among neoplastic cell populations and have driven 
investment in CSC-specific therapeutic research (Gupta et al., 2009). 
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Figure 1.2 Nanoparticle deposition within a tumorous environment via the enhanced permeation and retention (EPR) effect. Nanoparticles travel 
throughout the blood stream and enter the tumor environment through perforations in blood vessels around cancerous tissue. Figure created using 
components courtesy of Servier (2016). 
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1.3.2 Treatment 
Modern clinically-approved cancer treatments exist as one of four major 
interventions: chemotherapy, radiotherapy (RT), hormonal therapy and surgical 
procedures. When one or more of these treatments is combined with the primary mode of 
treatment, those therapies are referred to as adjunctive (Cunningham, 2000). 
Technological advancements have led to improved efficiencies but much work remains to 
be done, especially in the diagnostic and targeted therapy research realms (Baumann et 
al., 2016; Helleday et al., 2008; Ramaswamy et al., 2001). Below is a general description 
of clinically-available and experimental cancer treatment options. 
1.3.2.1 Chemotherapy and Hormonal Therapy 
Chemotherapy uses drug formulations to combat complications due to cancer 
growth and spread. Chemotherapeutic drugs are tailored to inhibit cell proliferation by 
directly attacking reproduction capabilities (Nitiss, 2009). Research has also been 
devoted to targeting the vasculature supplies tumor growth depends on in conjunction 
with traditional chemotherapy (Ma and Waxman, 2008). Typically, chemotherapy 
treatments are administered intravenously; however oral supplements are also used in 
certain therapy regimens (Findlay et al., 2008). Hormonal therapy relies on inhibition of 
hormones (i.e. estrogen, progesterone) associated with cancer cell proliferation (Swain et 
al., 2013).   
1.3.2.2 Surgery 
Depending on the location and size of a tumor, surgical excision may be a viable 
treatment option. In advanced cases of breast cancer, surgeons may be forced to complete 
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a mastectomy, where the entire breast is removed along with the primary tumor. In more 
ideal cases, tumor proliferation is limited and the breast may be spared. Recent 
technological advancements have made tumor removal easier and more efficient. Olson 
and co-workers (Veiseh et al., 2007) have developed a method for surgeons to 
differentiate between cancerous and non-cancerous solid tissue intra-operatively through 
use of a near-infrared-emitting fluorescent compound (Veiseh et al., 2007). In more 
extreme cases where tumors reside in locations such as the brainstem, effective surgery 
becomes increasingly difficult and treatment may be limited to medicinal and radiation-
based palliative therapies (Lamm et al., 2013). 
1.3.2.3 Radiation Therapy 
Radiation therapy (RT) uses targeted beams of radiation to deposit energy into 
tumor tissue, resulting in severe biological effects in and around the dosage site. RT relies 
on either direct or indirect action to induce double strand breaks in target DNA, leading 
to replication inhibition (Lomax et al., 2013). Direct RT directly interferes with the 
atomic structure of the target molecule. The atoms of the target molecule are either 
ionized or excited and this results in biological change (Hall and Giaccia, 2012). 
Conversely, indirect radiation produces reactive species from molecules other than the 
target molecule (i.e. water), which in turn disrupt the target’s atomic structure. As with 
the action radiation carries out, ionizing radiation also comes in direct and indirect forms. 
Directly ionizing radiation refers to the fact that the radiation source is itself charged (i.e., 
proton or electron beam sources). Alternatively, indirectly ionizing radiation refers to 
radiation sources wherein the source is charge-neutral (i.e., neutron and X-ray beam 
sources) (Hall and Giaccia, 2012) . Direct and indirect ionizing radiation forms are able 
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to cause DNA damage by both direct and indirect actions. RT doses are typically 
quantified in the SI unit, Gray (Gy), defined as Joules (J) of energy absorbed per 
Kilogram (Kg) mass (Agency, 2010). Side effects associated with radiation therapy 
depend on the treatment area as well as intensity and duration of exposure but may 
include swelling, bone marrow suppression, radiation fibrosis, cognitive impairment and 
a decreased chance of successful reconstructive breast surgery (Acharya et al., 2009; Hall 
et al., 2004; Hojan and Milecki, 2014; Kronowitz and Robb, 2009; Li et al., 2011). 
1.3.2.4 Photothermal Therapy 
Photothermal therapy (PTT) utilizes substances or metallic nanoparticles that 
produce heat upon photon irradiation, leading to the destruction of nearby cells and 
tissues. The process is largely dependent on the nanoparticle’s surface plasmon resonance 
(SPR), defined as the oscillation capability of surface electrons upon irradiation with light 
having a corresponding frequency. When irradiated with a range of wavelengths, peaks 
associated with maximum electron oscillation or amplitude emerge in absorbance spectra 
(Newhouse et al., 2011). These SPR peaks can be tuned by changing the shape, size and 
chemical make-up of the particular nanomaterial in question. The heat-producing 
phenomenon has been the subject of in-depth investigation by El-Sayed and co-workers 
(Huang and El-Sayed, 2010). Changes in electron oscillations upon irradiation result in 
electron-electron collisions and subsequent energy transfer from affected electrons to 
nearby phonons. Recent studies have highlighted efforts to target PTT-active 
nanomaterials to cancer cells and tumor sites with hollow gold nanospheres (HNGs), gold 
nanorods (AuNRs) and gold nanocages (AuNCs) being among the most commonly used 
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(Dykman and Khlebtsov, 2012; Lu et al., 2009; Melancon et al., 2008; Yang et al., 2013; 
You et al., 2010). 
In 2003, Hirsch and co-workers used silica-based gold nanoshells to complete 
PTT studies on breast carcinoma in vitro and in vivo (Hirsch et al., 2003). Cancer cells 
were incubated with nanoparticle-containing media for 1 hour then exposed to near-
infrared light (820 nm, 35 W/cm) for 7 min.  Cell samples treated with nanoparticles and 
NIR underwent local temperature increases, resulting in irreversible cellular damage. 
Subsequent studies have demonstrated effective targeting strategies to deliver high 
concentrations of HGN and AuNR to cancer sites through use of ligands including RNA 
and DNA-based aptamers and protein antibodies. When designing these nanoparticles, 
SPR peaks are optimally tuned to the near infrared wavelengths (800-950 nm) where 
tissue penetration is optimal and where absorbance by biological molecules is low. In 
2014, one report highlighted the enhanced tumor killing potential of a HGN-based 
treatment using RT, PTT and chemotherapeutics (Jeong, 2014).
 
Targeting ligands were 
not utilized in the study and systematic experimentation into the enhanced response was 
not completed. Subsequent research into combinational RT-PTT therapy against cancer is 
scarce despite the potential advantages such tandem therapy may offer.  
1.3.3 Impact of Cancer on Canadians 
The socio-economic and emotional impacts attributable to cancer are far-reaching 
and well understood. In 2000, cancer diagnosis and treatment cost Canadians 2.6 billion 
in health care coverage and another 14.8 billion in lost wages and productivity. Over 
200,000 Canadians were projected to receive a cancer diagnosis in 2014, making 
treatment of the disease an expensive and formidable health-care task (Statistics, 2015). 
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Recent studies have reported increasing treatment costs and have cited the stressful 
atmosphere in which healthcare policy-makers must make decisions (de Oliveira et al., 
2013; Meropol et al., 2009). Changes in chemotherapy and radiotherapy use among 
breast cancer patients are particularly startling, with dramatic increases witnessed in all 
age categories (de Oliveira et al., 2013). Today, the probability of a Canadian dying from 
cancer is 1 in 3.8, accounting for about 9 deaths per hour (Statistics, 2015).
 
1.4 Active and Passive Drug Targeting 
Nanoscale drug delivery platforms rely on either active or passive targeting 
methods to attack and kill cancer in the body. Passive targeting relies on the previously-
mention EPR effect. Here, the so-called “leaky” vasculature leading into the tumor 
microenvironment is taken advantage of. The integrity of the vasculature within the 
tumor microenvironment suffers from ~400 nm-sized holes and when a targeting ligand 
or delivery vehicle is smaller than the aperture, enhanced deposition of nanoconjugates 
will be evident, increasing the local concentration of drugs around the tumor. 
Active targeting relies in part on the EPR effect in order to reach the tumor 
microenvironment but also in specific targeting ligand interactions with cancer cells 
within the tumor. Antibodies and nucleic acid aptamers are widely recognized for this 
purpose. Frequently, these ligands bind with high affinity to over-expressed proteins 
found on the surface of cancer cells in order to carry drugs or nanoparticles to the 
cancerous site. While antibodies have advanced further at present in terms of clinical use 
and development, there are a number of advantages to employing aptamers for drug 
targeting in medicine. Aptamers are smaller than antibodies and are chemically 
synthesized, therefore there is no need for complicated in vivo preparation methods 
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(Jayasena, 1999). Furthermore aptamers show higher stability in harsh conditions and can 
be easily chemically modified with specific functional groups. Still, aptamers are 
sensitive to nuclease degradation, a major roadblock for in vivo application. With respect 
to this issue, DNA-based aptamers are recognized to have enhanced stability over their 
RNA-based counterparts (Kim and Paeng, 2014). 
1.5 Doxorubicin 
The anti-cancer characteristics of Doxorubicin (DOX) were discovered in the 
1950’s and the drug was first approved for clinical use over 30 years ago (Judson et al.). 
Since then a host of new cancer drugs have been developed and range in their utility in 
the clinic depending on the type of cancer as well as to what extent acquired and inherent 
chemo-resistance are displayed by the patient (Voulgari and Pintzas, 2009). DOX has 
stood the test of time as a clinical agent and remains a frontline chemotherapeutic in 
many cancer therapy regimens (Gabizon et al., 2003). Likewise, its use as a model drug 
in delivery system design research has been sustained over the past three decades, owing 
in large part to its water solubility and fluorescence characteristics, which make it 
exceptionally easy to use in research applications (Ahmad et al., 1993; Aryal et al., 2009; 
Wang et al., 2013).  
1.5.1 Chemical Structure 
DOX (Figure 1.2) is chemically defined as an anthracycline molecule owing to its 
tetracyclic anthracene-like group being linked to an amine-containing sugar moiety 
(Arcamone et al., 1972). The planar tetracyclic portion of the molecule is a chromophore 
with fluorescence in the UV-Vis region of the electromagnetic spectrum and is active in 
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DNA intercalation. DOX has a pKa of 8.3 and is therefore protonated at physiological pH 
due to its amine moiety, which has been proposed to facilitate electrostatic interactions 
with various nanomaterials. The carbonyl groups of ring 2 provide potential sites of 
coordination with metallic nanomaterials and hydrogen bonding, as does the nitrogen-
containing amine moiety of ring 5. The electron-rich tetracyclic system of the drug also 
provides the potential for π- π stacking and hydrophobic interactions (Liu et al., 2007). 
Taken together, DOXs complex structural features lead to a number of interaction 
possibilities with nanomaterials currently used in biomedical and nanotechnology 
research. Better understanding the nature of DOX interaction and adsorption mechanisms 
as well as the accompanying release mechanisms will help to enhance and justify future 
drug delivery system development and investigation at the nanoscale. 
 
Figure 1.3 Chemical structure of Doxorubicin 
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1.5.2 Applications in Nanomedicine 
Over the course of the last decade, numerous nanoscale-DOX formulations have 
demonstrated increased therapeutic efficiency both in vitro and in vivo. These 
formulations have proven novel in terms of their loading efficiencies as well as in the 
ways they evade difficult clinical impediments. Multi-drug resistance (MDR) remains a 
major hindrance for many therapeutic agents and nanotechnology has allowed for the 
development of ‘stealth’ vehicles in order to evade rapid drug efflux (Li et al., 2009). 
Further, many nanoparticle-delivery systems, through their ease of functionalization, are 
able to accommodate co-adsorption of polymers such as polyethylene glycol (PEG) for 
increased in vivo circulation times (Maruyama et al., 1992). In 2011, Wang and co-
workers (Wang et al., 2011) demonstrated a gold nanoparticle-based doxorubicin delivery 
system wherein a pH-sensitive tethering technique was used to link DOX to the 
nanoparticle. The system was able to evade MDR and efficiently kill MDR+ cells 
through enhanced cellular uptake and drug release within acidic organelles. Moreover, 
the authors employed the fluorescent character of doxorubicin to probe drug release 
within the cells by monitoring the enhanced fluorescence upon release from the 
nanoparticle.  
In 2009, Park and co-workers (Park et al., 2009) employed a dual-therapy 
platform wherein DOX was encapsulated within the core structure of poly(lactic-co-
glycolic acid-gold shell nanoparticles. Upon irradiation with NIR light corresponding to 
the absorbance maximum of the gold shell, photothermal and chemotherapeutic cell 
killing was facilitated by increased local temperature and nanoparticle degradation-
induced drug release. This study, and others like it, shed light on the therapeutic potential 
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hyperthermia-chemotherapy platforms embody following intelligent conjugate design. 
The authors demonstrate that the combinatory platform exceeded the additive cell killing 
potential attributable to the independent therapies, thereby demonstrating a synergistic 
therapeutic effect.  
1.6 Polyethylene Glycol 
Polyethylene glycol (PEG) is chemically defined as a long-chain polyether 
compound having both hydrophobic and hydrophilic components (Hu et al., 2007) 
(Figure 1.4). Polyether portions of the molecule allow for some degree of hydrophobic 
interactions, while the oxygen atoms and hydroxyl moieties allow for hydrogen bonding 
giving the compound a high degree of water solubility of up to 20% w/w for even high 
molecular weight PEG (20,000 g/mol). These components lead to interesting application 
potentials in fields of research such as drug delivery (Knop et al., 2010), spinal cord 
injury repair (Luo et al., 2002) and biosensor development (Liu et al., 2013). 
 
Figure 1.4 Chemical structure of polyethylene glycol. 
1.6.1 Applications in Nanomedicine 
PEG has been extensively used in drug delivery studies owing to its unique 
chemical properties in solution (Knop et al., 2010). Depending on the application of 
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interest, different weight-PEG molecules may be employed whereby extension of the 
repeating polyether unit, leads to increased molecular weight. PEG has found much 
success in the development of liposomal-based drug delivery systems (Gabizon, 2001). 
Perhaps most notably is liposomal doxorubicin, which comes in both PEGylated and un-
PEGylated forms. Lipid molecules that make up the high molecular weight PEG can be 
conjugated to the hydrophilic terminal end of the lipid molecules used to form the 
liposomal drug vehicle. PEGylation results in increases in the effective size, weight and 
blood circulation time of the nanocarrier in vivo. In turn this has resulted in PEGylated 
nanoparticles being referred to as so-called ‘stealth’ delivery vehicles (Knop et al., 2010; 
Lasic and Needham, 1995). 
1.7 Objectives 
The thesis explores several important questions related to the use doxorubicin and 
gold nanoparticles in cancer therapy research. The specific objectives of the thesis were 
to: 
1. Develop a novel method for the accurate quantification of DOX in drug delivery 
studies using polyethylene glycol. 
2. Investigate the nature of the interaction between DOX and citrate-capped AuNPs 
and survey the feasibility of simple DOX-AuNP conjugates in therapeutic 
applications.  
In chapter 2, doxorubicin adsorption to plate well surfaces is characterized and the 
inclusion of several polymer and protein-based reagents is studied as a means to decrease 
non-specific adsorption of the drug molecule to the plate surface. Trace amounts of 
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polyethylene glycol of high molecular weight are shown to adequately prevent such 
nonspecific adsorption and ensure both simple and robust quantitative methods. In 
chapter 3, a systematic study of the adsorption profile of doxorubicin onto citrate-capped 
gold nanoparticles is completed by varying chemical and physical parameters. In addition 
to systematic experimental evidence, theoretical modeling is provided to substantiate a 
cation-π- based interaction theory. 
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Chapter 2 Prevention of doxorubicin sorptive losses in drug 
delivery studies using polyethylene glycol 
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2.1 Summary 
The non-specific sorption of hydrophobic pharmaceuticals on reaction vessel 
surfaces raises serious analytical challenges for their accurate quantification. Systematic 
error due to sorptive loss of analytes may result in significant overestimation of drug 
loading on nanomaterial-based drug delivery systems (DDS), leading to inaccurate 
determinations of dosage and DDS efficiency. We evaluated sorptive losses of 
doxorubicin (DOX), an effective chemotherapeutic, in polystyrene based 96-well plates, 
and proposed a simple but effective method to prevent the non-specific sorption of DOX 
using trace concentrations of polyethylene glycol (PEG). Relative to widely-used 
proteinaceous and surfactant surface blocking agents, PEG is effective, easy to use, and 
does not interfere with drug loading to the DDS. 
2.2 Introduction 
Doxorubicin (DOX) is widely employed as an effective chemotherapeutic for 
treatment of various solid tumors, but is associated with significant adverse side effects 
including cardiomyopathy, potentially resulting in congestive heart failure. (Chatterjee et 
al., 2010; Singal and Iliskovic, 1998). To address this issue, research into drug delivery 
systems (DDSs) that use nanomaterial-based drug carriers designed with targeting 
functionality could enhance DOX effectiveness by delivering high drug concentrations 
directly to cancerous tissues (Kong et al., 2014). Such a DDS would decrease both 
required concentrations, and by being targeted, reduce adverse side effects in blood and 
other organs (Allen and Cullis, 2004; Bagalkot et al., 2006; Hrubý et al., 2005; Kataoka 
et al., 2001; Kwon et al., 1997). Accurate quantification of drug loading capacity to 
nanomaterials is not only critical to evaluate the efficacy of the nano-drug carriers in 
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DDS development research, but also important to determine the dosage of the DDS for 
clinical trials. However, quantitative evaluations of DDS efficacy have been significantly 
hampered by the non-specific sorption of DOX to various plastic containers during 
storage and analysis (Tomlinson and Malspeis, 1982; Wood et al., 1990b; Wu and Ofner, 
2013),
 
with photo-degradation further deteriorating data quality (Beijnen et al., 1986; 
Janssen et al., 1985; Wood et al., 1990a). Gold nanoparticles (AuNPs) are an example of 
nano-drug carriers for DDS development. When evaluating the loading capacity of DOX 
onto AuNPs, there are three experimental steps: drug loading to AuNPs, separation of 
free DOX from bound fractions (i.e., DOX-AuNP conjugates), and instrumental 
quantification of the free fraction. The loading capacity of DOX to each AuNP is 
measured by the optical signal difference (absorbance or fluorescence) before and after 
DOX loads to the nanoparticles, as shown in Eq. 1. 
                                        (1) 
Where NLoading is the number of DOX adsorbed to each AuNP, Ctotal and Cfree are the total 
and free concentration of DOX, and CAuNP is the concentration of AuNPs in the drug 
loading system. Any DOX adsorbed to the container surfaces (e.g., microcentrifuge 
tubes, micropipette tips, or 96 well plates), is attributed by Eq.1 to the loading capacity of 
AuNPs for DOX, which can overestimate the loading capacity of the drug carriers. The 
assumption underlying such calculations is a negligible sorptive loss of DOX, which in 
reality has been disproven in several studies (Tomlinson and Malspeis, 1982; Wood et al., 
1990b; Wu and Ofner, 2013).  
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To date, the adsorption of DOX to various material surfaces including glass, 
siliconized glass, polyethylene, polypropylene, polytetrafluoroethylene, 
polyvinylchloride, and cellulose dialysis membranes has been well documented 
(Tomlinson and Malspeis, 1982; Wood et al., 1990b; Wu and Ofner, 2013). However, 
there is no data for the adsorption of DOX on polystyrene 96-well plates, which are 
routinely used for laboratory fluorescence quantification. Systematic non-specific 
sorption experimental error, if present, would seriously affect fluorescence 
measurements, leading to false conclusions. Further, there is little research on approaches 
to prevent DOX sorptive losses and ensure analytical accuracy, despite the drug’s 
widespread use in this context (Fan et al., 2014; Mohan and Rapoport, 2010; Ren and 
Wei, 2004). To address these problems, we propose a simple but effective method to 
prevent sorptive losses by incorporating trace (part-per-million) concentrations of 
polyethylene glycol (PEG) into the buffer used to dissolve DOX (shown in Figure 2.1).  
Critically, the addition of PEG does not interfere with the loading of DOX to nanoparticle 
surfaces, thereby ensuring accurate quantification of drug loading capacity. 
2.3 Materials and Methods 
2.3.1 Chemicals 
PEG, Bovine Serum Albumin (BSA), Tween-40, Triton X-100, HEPES and 
doxorubicin hydrochloride were purchased from Sigma-Aldrich. Ethylene glycol was 
purchased from Alfa Aesar (Ward Hill, MA) while polystyrene 96-well plates were 
purchased from Corning Inc. (NY) and microcentrifuge tubes (Cat. No. 02-681-284; Lot 
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No.: 13300434) and ethanol were purchased from Fisher Scientific (Ottawa, ON, 
Canada). Nanopure 18.2 MΩ-cm water was used in all experimentation.  
2.3.2 Doxorubicin Adsorption Kinetics and Isotherm 
In all experiments, doxorubicin was quantified by fluorescence measurement 
(excitation/emission: 480 nm/580 nm) using a TECAN Infinite M10000 PRO micro-plate 
reader. Polystyrene 96-well plates (Costar 3915, Lot No.: 26313022) were used in all 
quantification experiments with working volumes of 100 μL in each well, with the 
exception of isotherm determination where sample volume was increased to 150 μL to 
offset evaporation during extended measurement times (90 min, n=3).  
Doxorubicin stock solution (5 μM in Nanopure water stored in a 1.5-mL amber 
tube at -20
o
C) were added to wells containing varying volumes of HEPES buffer (5 mM, 
pH 7.6 to a final volume of 150 μL in each well) to achieve DOX concentrations ranging 
from 0.25 to 2.5 μM. DOX adsorbed onto the plate surface was determined by recording 
the decrease in fluorescence over 90 min. The calibration was performed against a 
standard curve whose solutions included 10 ppm of PEG 20K.  
To determine the role of blocking agents on non-specific DOX adsorption to 96-
well plate surfaces, DOX adsorption kinetics were monitored in the presence of various 
molecular weights (1K, 2K, 4K, 8K, and 20K) and concentrations of PEG. DOX aqueous 
solutions without any blocking agents added served as the control. Typically, 80 μL of 
HEPES buffer (5 mM, pH 7.6) were mixed with 10 μL of PEG solution in each well, 
followed by 10 μL of doxorubicin solution for a final volume in each well of 100 μL. The 
mixture was gently mixed before recording fluorescent signals over defined intervals 
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(i.e., 6 - 10 min). The identical procedure was repeated for other surface blocking 
reagents including BSA, Tween-40, and Triton X-100.  
The kinetics and capacity of citrate-stabilized AuNPs for DOX adsorption in the 
presence or absence of blocking reagents (n = 3) was evaluated by fluorescence change 
over time before and after blocker addition. The final volume of solution in each well was 
100 μL, comprising 70 μL of 5 mM HEPES buffer, 10 μL of surface-blocking reagent 
solution (PEG, BSA, Tween-40, or Triton X-100), 10 μL of DOX stock solution (5 μM in 
Nanopure water) and 10 μL of (10 nM) AuNP solution.  
2.3.3 Microcentrifuge Tubes 
PEG was evaluated as a blocking agent against doxorubicin adsorption onto 
surfaces of microcentrifuge tubes (n = 3). Briefly, 10 μL of PEG 20K (1000 ppm) was 
added to 80 μL of Nanopure water with varying concentrations of NaCl (0, 15, 30, 60, 90, 
120, 150 mM) and gently mixed by shaking (control tubes contained an additional 10 μL 
of HEPES buffer instead of PEG solution). To this mixture, 10 μL of doxorubicin stock 
solution (75 μM) was added into the tubes and gently mixed again. After 10 min, 10 μL 
of this mixture was combined with 90 μL of HEPES-PEG buffer (PEG 20K: 10 ppm) in 
the 96-well plate for fluorescence measurements. In this experiment, the HEPES-PEG 
buffer was used to prevent DOX adsorption to the plate wells, so our results only reflect 
adsorption to microcentrifuge tube surfaces. 
2.3.4 Doxorubicin Degradation Studies 
The potential protective ability of PEG to inhibit the photodegradation of DOX was 
evaluated using a Safe Imager™ Blue Light Transilluminator. Briefly 1 mL of DOX 
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stock solution was added to a 10 mL clear glass vial (n = 3). Increasing concentrations of 
PEG 20K were added to achieve a final volume of 1.5 mL before solutions were mixed 
and capped. Vials containing DOX-PEG were then exposed to the blue light source (λ = 
470 nm) from the Transilluminator for increasing time intervals with doxorubicin 
fluorescence measured kinetically (10 μL of sample solution and 90 μL of HEPES-PEG 
buffer in the plate well). 
2.4 Results and Discussion 
2.4.1 Sorptive Losses of DOX 
The sorptive loss of DOX onto various experimental plastic containers might 
seriously compromise quantitative evaluations of drug delivery system (DDS) 
performance (Tomlinson and Malspeis, 1982; Wood et al., 1990b; Wu and Ofner, 2013). 
For example, if loading 10 μM DOX to gold nanoparticles (AuNPs), the DOX 
concentration is normally 10
2
-10
5
 times that of the concentration of the nanomaterials for 
experimental use (for example, the concentration of widely used 13 nm AuNPs is about 
10 nM). Under these conditions, 20-50% (2-5 μM) cumulative sorptive losses could be 
expected during multi-step-experiments (including drug loading, centrifugation in 
polypropylene microcentrifuge tubes, and during quantification in 96-well plates). 
Consequently, the total available concentration of DOX in the solution would be 50-80% 
(i.e., 5-8 μM) of the originally added concentrations. If we assume the real loading 
capacity is 500 DOX/AuNP, the calculated loading capacity would be 700-1000 
DOX/AuNP, which would be 40-100% overestimated; such overestimates result in 
unreliable conclusions.  
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Figure 2.1 Schematic representation of DOX sorptive losses via non-specific adsorption to plate 
wells (A) and prevention of non-specific sorptive losses of DOX by inclusion of PEG (B). 
 
The non-specific sorption of DOX to polypropylene microcentrifuge tubes was 
evaluated as these tubes are among the most frequently used plastic vessels in laboratory 
experiments. The adsorption of DOX (7.5 µM DOX in 100 µL 5 mM HEPES buffer, pH 
7.6) onto polypropylene tube surfaces decreased fluorescent signal intensities ~ 20% over 
30 min; lower DOX concentrations (0.25 µM) experienced relatively greater sorptive 
losses of 40% over 10 min (Figure 2.2B), which is consistent with previously published 
data (Tomlinson and Malspeis, 1982). To elucidate the mechanism of DOX adsorption, 
the influence of NaCl, ethanol, and ethylene glycol on the amount of DOX adsorbed to 
the tube was evaluated. Adsorption would be essentially attributable to electrostatic 
interactions if the addition of NaCl decreased adsorption due to the charge screening 
effect, while adsorption would be primarily driven by hydrophobic interactions if the 
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presence of organic solvents (EtOH and EG) decreased sorptive losses of DOX. Sorptive 
DOX losses were in fact unaffected by NaCl concentrations (Figure 2.2A) but reduced by 
ethanol and ethylene glycol (EG, as discussed later) indicating DOX adsorption to 
container surfaces is governed by hydrophobic rather than electrostatic interactions. 
We next evaluated DOX sorptive losses in polystyrene 96-well plates, which are 
again widely used for fluorescence-based DOX quantification. DOX loading capacity, as 
observed by Langmuir isotherm, was determined as 520 nM per well on 96-well plates 
(Figure 2.2C). At 520 nM, assuming the size of each DOX molecule is about 3.17 nm
2
 
with a diameter of 1 nm, (based on the theoretical estimation of DOX molecule size of 
1.026 nm in diameter using the Global Minimum approach at the lowest energy) we can 
determine each 100 µL well working volume can adsorb 3 X 10
13
 DOX molecules on 
each 95 mm
2
 useable well surface. The Langmuir isotherm and aforementioned 
calculations support a monolayer adsorption model. The adsorption of DOX to plate well 
surfaces is a relatively fast process with the adsorption-desorption equilibrium achieved 
within 40 min (Figure 2.2B), a typical time interval for drug adsorption experiments with 
nanomaterials (Wang et al., 2013; Wang et al., 2011). 
2.4.2 PEG Effect on Sorptive Losses of DOX 
Currently, there are several established agents used for surface blocking including 
BSA and the surfactants Tween and Triton X-100, which are efficacious in preventing 
sorptive losses in various bioassays (Liu et al., 2013). However, these traditional blocking 
methods have limitations such as additional and time-consuming plate treatment steps 
(e.g., 0.5-12 h for BSA blocking), generating air bubbles in the sample solution during 
mixing, and potential for interference with DOX loading onto nanomaterials. All of these
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Figure 2.2 Sorptive losses of doxorubicin to polypropylene micro-centrifuge tubes (A) and polystyrene 96-well plates (B and C). (A) The effect of salt 
and/or PEG 20K on DOX sorption onto microcentrifuge tube surfaces. In the control tube, no chemicals other than DOX aqueous solution were added. 
(B) Decrease in the fluorescence of various DOX concentrations (from 0.25 to 3.5 µM) within plate wells over time; (C) the Langmuir isotherm for non-
specific sorption to plate-well surfaces. 
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technical issues can be overcome by using low concentrations of PEG as the blocking 
agent. The presence of 10 ppm of PEG 20K in the plate wells produces neither air 
bubbles nor inhibition of DOX loading, as evidenced by retention (of around 100%) of 
DOX fluorescence intensity (Figure 2.3). Initially, we tested the effects of PEG molecular 
weight (MW) and concentration on DOX adsorption to the surfaces of polystyrene plate 
wells (Figures 2.3 and A.1). This trial demonstrated that although PEG 1000 is helpful (~ 
98% of DOX was retained, only 2% sorptive loss), PEG of larger MW were more 
effective. For example, only 10 ppm of PEG 20K (0.5 µM) demonstrated comparable 
blocking efficacy as 100 ppm of PEG 4K or 1000 ppm of PEG 1K (Figures 2.3 and A.1).  
Consequently, the role of PEG MW and concentration on sorptive loss of DOX was 
systematically evaluated (Figure A.1), producing the conclusion that 10 ppm of PEG 
8000 is generally effective in addressing sorptive DOX losses in 96 well plates. Similar 
blocking protection for DOX in the presence of 10 ppm of PEG 20K within 
polypropylene microcentrifuge tubes was observed (Figure 2.2A), indicating the 
universality of PEG blocking in plastic vessels, which is consistent with results 
demonstrated in homogeneous biosensor development (Liu et al., 2013). 
There are two potential mechanisms contributing to PEGs’ reduction of sorptive 
losses of hydrophobic drugs such as DOX from the drug loading solution (Figure 2.1). 
First, PEG molecules, especially those of higher molecular weight (i.e., ≥ 4K), can adsorb 
to plate surfaces, preventing DOX adsorption as evidenced by the Langmuir adsorption 
isotherm (Figure 2.2C) (Liu et al., 2013; Zhang et al., 2012b, c).  The second possible 
mechanism is that the addition of PEG decreases the aqueous buffer polarity, thereby 
increasing DOX solubility, as observed and utilized in organic synthesis by other groups 
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(Chen et al., 2005; Herrmann et al., 1983; Hirano et al., 2012).
 
 If PEG was in fact 
modifying the polarity of the solution, we would expect molecules with similar properties 
to exert similar effects. Our results with ethanol and EG also support this mechanism, as 
10% ethanol or EG significantly alleviated sorptive losses of DOX relative to a control 
lacking ethanol or EG, albeit less effective than 10 ppm of Tween 40, Triton X-100, or 
PEG 20K (Figure 2.4).  
 
Additionally, it is also possible DOX could bind to PEG molecules, reducing 
DOX molecule polarity and thereby increasing solubility. We tested this potential 
mechanism by studying if DOX was adsorbed to PEG-coated AuNPs (pre-functionalized 
with thiolated PEG 2K). Since AuNP is an excellent fluorescence quencher (based on 
nanoparticle surface-energy transfer (NSET), it would quench the fluorescence of DOX 
upon binding (Daniel and Astruc, 2004; Dulkeith et al., 2002; Mayilo et al., 2009).
 
However, after DOX solution was added to the PEG-SH-AuNP solution and incubated 
Figure 2.3 The effects of PEG (various concentrations and molecular weights) on DOX 
adsorption onto 96 well plate surfaces. In the control wells, no chemicals other DOX aqueous 
solution were added. 
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under room temperature for 30 min, no DOX adsorption (as evidenced by fluorescence 
quenching) was observed by monitoring the fluorescence intensity of the supernatants. 
All DOX signals were recovered by centrifugation, demonstrating DOX does not adsorb 
to PEG (data not shown). 
2.4.3 PEG Effect on DOX Loading on Gold Nanoparticles 
As mentioned previously, many surface blocking agents, when employed to 
prevent sorptive losses of DOX to plastic vessel surfaces, may also block the surface of 
the drug carrier (i.e., gold nanoparticles in the current work), significantly affecting drug-
loading capacity. We compared several surface blocking reagents (i.e., BSA, Triton X-
100, Tween 20, and PEG 20K) for their capacity to prevent sorption of DOX to 
polystyrene plate wells (as shown in Figure 2.4) but also their interference of DOX 
loading to AuNPs. DOX solution fluorescence in plate wells was recorded over 10 min in 
the presence of these various blocking reagents (10 ppm) with AuNPs added into each 
well after 240 s.  Over the first 240 s, there was a 19% decrease in DOX fluorescence (as 
indicated by the distance a) for the control sample (no blocking reagent) in the plate 
wells; in contrast, Triton X-100, Tween and PEG 20K maintained a near constant 
fluorescence level, indicating they effectively prevented sorptive losses of DOX to plate 
well surfaces (Figure 2.5). However, 10 ppm BSA did not prevent the DOX adsorption to 
the plate surface, which is reasonable considering the hydrodynamic diameter of BSA 
(~7 nm) and the high protein binding affinity of DOX (~75%).  Presumably, DOX 
adsorbed to plate well surfaces between adjacent BSA molecules, and/or to BSA itself, 
forming BSA-DOX conjugates.  
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Interference of DOX loading to AuNP surfaces was evaluated by comparing 
fluorescence quenching after addition of AuNPs in the system after 240 s. These results 
demonstrate 10 ppm of PEG 20K and Triton X-100 did not block DOX loading to AuNPs 
any more than the control (lacking blocking agents), while Tween and BSA inhibited 
DOX loading to the greatest degree. Additional evidence was obtained by directly 
comparing the number of DOX molecules sorbed onto AuNP surfaces in the presence or 
absence of PEG 20K (Figure A.2); critically, the amount of DOX loaded to AuNPs was 
independent of the presence of PEG 20K (p = 0.0647). Conversely, Tween and BSA may 
inhibit DOX loading to AuNPs by directly blocking AuNP surfaces, or by decreasing free 
DOX available to bind AuNPs by binding to DOX themselves. 
Unlike BSA, which is commonly pre-coated to block non-specific adsorption in 
biochemical assays such as enzyme-linked immunosorbent assays (ELISAs), PEG 20K 
must be added into the system concurrent with other reagents (DOX and AuNPs). This 
was evident from our experiment directly testing the effectiveness of PEG 20K and other 
surface-blocking agents to pre-coat plate wells in a separate step similar to that where 
BSA is used as a blocking agent of ELISA plates. In our experiment, plate wells were 
treated with 1% (v/v) BSA, PEG 20K, Tween 40, and Triton X-100 (100 ppm) in HEPES 
buffer (5 mM, pH 7.6) for 30 min at room temperature. After incubation, these pre-coated 
plate wells were rinsed twice with HEPES buffer prior to DOX fluorescence 
measurement in HEPES buffer. Two controls were included in this experiment; the first, 
a positive control, for which the plate wells were treated only with HEPES buffer and the 
DOX solution contained 10 ppm of PEG 20K. The negative control plate wells contained 
only HEPES and DOX buffer solutions. DOX sorptive losses remained significant in the
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Figure 2.4 Comparison of several surface-blocking agents with 10% (v/v) ethylene glycol and 
ethanol. In the control wells, no chemicals other than DOX aqueous solution were added. 
 
PEG-treated plate wells, similar to those not receiving any pre-treatment, presumably as 
PEG binding to the plate surface was weak, and PEG was unable to adhere to the well 
surfaces during plate rinsing (Figure 2.6). Consequently, the simplest and most effective 
means of PEG preventing DOX sorptive losses is by including 10 ppm of PEG 20K into 
the buffer used to prepare DOX solutions. Similar to BSA, Tween and Triton X-100 are 
also unsuitable blocking agents for pre-treating plate wells. Although BSA did not reduce 
DOX’s sorptive losses when concurrently added (Figure 2.4) but rather interfered with 
DOX loading to AuNPs (Figure 2.5), it was however an effective pre-treatment blocker 
to prevent sorptive losses of DOX, although quite time-consuming and requiring extra 
steps.
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Figure 2.5 Inhibition of DOX loading to AuNPs by several surface blocking reagents (BSA, 
Triton X-100, Tween 20, and PEG 20K). AuNPs were introduced after 240 s; no surface blocking 
agents were added to control wells. 
 
Figure 2.6 Relative effectiveness of surface-blocking agents as assessed by monitoring DOX 
fluorescence in plate wells pre-coated with the various surface-blocking agents. 
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2.4.4 PEG Effect on Photo-Degradation of DOX 
In addition to sorptive losses, DOX can be photodegraded during storage or 
analysis upon light exposure (Beijnen et al., 1986; Janssen et al., 1985; Tomlinson and 
Malspeis, 1982; Wood et al., 1990a, b; Wu and Ofner, 2013). Previous studies 
demonstrated PEG-coated liposomes reduced UVA-induced photodegradation of 
encapsulated DOX (Bandak et al., 1999);  consequently, we investigated if PEG 20K 
could protect DOX from blue light (λ = ~ 470 nm) degradation. Photodegradation of 
DOX was reduced to less than 2% following a 1 min exposure in buffer containing 8000 
ppm (or 0.8%) PEG 20K (Figure 2.7). Even in the presence of only 10 ppm PEG 20K, 
74% of intact DOX remained after 1 min light exposure, in contrast to 58% remaining 
when PEG was absent. Notably, even if 8000 ppm PEG 20K was present, 
photodegradation continued increasing over time. The protective mechanism of PEG 20K 
is presumably via decreasing DOX adsorption onto the inner vial surfaces, where the 
distance between DOX molecules and photons is minimal and photodegradation of DOX 
is maximized.  
Interestingly, the protective effect of PEG 20K increased with increased PEG 
concentrations, a phenomena for which the underlying mechanism is not yet clear but 
deserving of future investigation. There are several facts contradictory to established 
mechanisms for PEG enhancing DOX photo-stability; first, PEG 20K does not absorb 
blue light (Figure A.3). Second, the DOX concentrations are low (5 µg/mL) and 
insufficient for concentration-induced self-protection. Third, the PEG 20 K buffer pH 
was 7.6, while it is acidic buffer that facilitates the ready degradation of DOX (Janssen et 
al., 1985; Wood et al., 1990b; Wu and Ofner, 2013). 
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Figure 2.7 DOX photodegradation kinetics in solutions containing various concentrations of PEG 
20K. The control sample was not exposed to blue light. 
 
2.5  Conclusions 
In summary, this work demonstrates small amounts of PEG (ppm level) can 
effectively protect DOX from sorptive losses, and to a limited extent, from 
photodegradation. Collectively, our data suggests PEG holds promise for use in storage, 
transportation, and accurate evaluations of drug delivery systems by reducing non-
specific adsorption, a common experimental artifact
 
and analytical challenge in drug 
analysis. Therefore, this work has wide implications for drug analysis in the 
pharmaceutical industry and has additional application for environmental scientists.  
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3.1 Summary 
Gold nanomaterials have received great interest for their use in cancer theranostic 
applications over the past two decades. Many gold nanoparticle-based drug delivery 
system designs rely on adsorbed ligands such as DNA or cleavable linkers to load 
therapeutic cargo. The heightened research interest was recently demonstrated in the 
simple design of nanoparticle-drug conjugates wherein drug molecules are directly 
adsorbed onto the as-synthesized nanoparticle surface. The potent chemotherapeutic, 
doxorubicin often serves as a model drug for gold nanoparticle-based delivery platforms; 
however, the specific interaction facilitating adsorption in this system remains 
understudied.  Here, for the first time, we propose empirical and theoretical evidence 
suggestive of the main adsorption process where 1) hydrophobic forces drive doxorubicin 
towards the gold nanoparticle surface before 2) cation- π interactions and gold-carbonyl 
coordination between the drug molecule and the cations on AuNP surface facilitate DOX 
adsorption. In addition, biologically relevant compounds, such as serum albumin and 
glutathione, were shown to enhance desorption of loaded drug molecules from AuNP at 
physiologically relevant concentrations, providing insight into the drug release and in 
vivo stability of such drug conjugates. 
3.2 Introduction 
3.2.1 Doxorubicin 
Doxorubicin (DOX), an anthracycline chemotherapeutic, remains at the forefront 
of malignant breast, leukemic and sarcoma cancer treatment more than 30 years after its 
clinical inception and FDA approval (Judson et al., 2014) Despite its widespread usage, 
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DOX is often associated with multidrug resistance as well as adverse side effects such as 
nausea, hair loss and acute and chronic cardiotoxicity, the latter potentially leading to 
congestive heart failure (Anderson et al., 1981; Chatterjee et al., 2010; Gottesman et al., 
2002; Hesketh and Sanz-Altamira, 2012). Liposomal formulations of DOX have led to 
improvements in the drug’s efficiency but the development of advanced targeted drug 
delivery system (DDS) platforms for DOX remains a worthwhile research endeavor 
receiving substantial investment (Allen and Martin, 2004; Bagalkot et al., 2006; Gabizon 
et al., 1994; Gabizon et al., 2003; Kim et al., 2010). An ideal targeted DOX delivery 
platform would decrease required concentrations as well as the prevalence and intensity 
of side effects associated with the drug, all while utilizing its potent anti-cancer properties 
(Jean et al., 2015). 
3.2.2 Gold Nanoparticles 
Gold nanoparticles (AuNPs) have become an  increasingly popular DDS 
development in recent years (Cheng et al., 2008; Ghosh et al., 2008a; Ghosh et al., 
2008b; Paciotti et al., 2006; Zhang et al., 2011). High biocompatibility, tunable surface 
chemistry, and unique optical properties make nanogold a desirable platform for many 
biomedical applications (Arvizo et al., 2010; Saha et al., 2012; Shukla et al., 2005; Zhao 
and Liu, 2014). Further, AuNPs have been commercialized for use in diagnostic 
applications and are involved in clinical-phase trials (Jans and Huo, 2012; Libutti et al., 
2010; Park et al., 2009). Numerous studies have highlighted AuNPs promise in the 
targeted delivery of anticancer drugs including DOX to cancerous cells and tissue (Cheng 
et al., 2008; Wang et al., 2011). Gold nanorods (AuNRs) and hollow gold nanoparticles 
(HGNs) allowing for the absorption of tissue-penetrating near-infrared (NIR) light have 
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been successfully used in combinational chemo-photothermal therapy (PTT) and imaging 
applications (Huang and El-Sayed, 2010; Kong et al., 2015; Lu et al., 2009; You et al., 
2010).
  
3.2.3 Doxorubicin Loading onto Nanoscale Gold 
Currently, there are two mechanisms for loading DOX to nanogold delivery 
vehicles (Figure 3.1). The first approach is through indirect attachment with thiolated 
anchor molecules such as methoxy-poly ethylene glycol (mPEG), (Aryal et al., 2009) 
double-stranded DNA rich with G-C base-pairs (Kim et al., 2010), and copolymers 
(Prabaharan et al., 2009). In this system, controlled release of DOX can be efficiently 
achieved via either temperature induced DNA melting or pH-sensitive cleavage (i.e., 
acid-cleavable hydrazone linkage) (Wang et al., 2011). The second approach is the direct 
adsorption of DOX onto gold surfaces (Elbialy et al., 2014; Mirza and Shamshad, 2011; 
You et al., 2010). DOX has been demonstrated to have high affinity for  various gold 
nanomaterials such as solid AuNPs, AuNRs and HGNs. HGNs showed exceptionally 
high loading of DOX due to their  high surface area (You et al., 2010). In contrast to the 
elegant, controllable, yet complicated indirect DOX loading procedure, direct adsorption 
is simple and straightforward, but the physiochemical interaction mechanism between 
DOX and AuNPs remains largely understudied, with only limited reports discussing 
potential interaction mechanisms available at present. In these reports, an electrostatic 
interaction between the positively-charged amine moiety of DOX and the negatively-
charged citrate that serves as the capping ligand on the surface of AuNPs is proposed to 
facilitate DOX adsorption, (Elbialy et al., 2014; Mirza and Shamshad, 2011) but, to date, 
such salt-bridging interactions have not been substantiated by systematic
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Figure 3.1 Schematic highlighting the various techniques used to load DOX to AuNP in drug delivery systems. 
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experimentation. The immense interest in AuNP-DOX based DDS development, together 
with limited mechanistic understanding of the system, motivated us to conduct more 
rigorous investigations better defining the physiochemical interactions driving DOX 
adsorption onto AuNP surfaces.  
3.3 Materials and Methods 
3.3.1 Chemicals 
Doxorubicin hydrochloride, glutathione, bovine serum albumin and the citrate 
assay kit were purchased from Sigma-Aldrich (St. Louis, MO). Polystyrene 96-well 
plates were purchased from Corning Inc. (NY) and microcentrifuge tubes (cat. no. 02- 
681-284), ethanol, methanol, and NaCl were purchased from Fisher Scientific (Ottawa, 
ON, Canada). KBr spectrograde powder was purchased from International Crystal Labs 
(Garfield, NJ). HEPES salt and trisodium citrate were purchased from Alfa Aesar 
(Parkridge Rd Ward Hill, MA). 7-Deoxy doxorubicin aglycone was purchased from 
Toronto Research Chemicals Inc. and anthracene was supplied by J.T.Baker chemicals. 
DOX-M was synthesized following reported protocols and confirmed with NMR and 
mass spectrometry (Liang et al., 2014). AuNPs were synthesized via the well-established 
citrate reduction method (Frens, 1973). Nanopure 18.2MΩ cm water was used in all 
experimentation.  
3.3.2 Doxorubicin Quantification 
Un-adsorbed or “free” doxorubicin was quantified by fluorescence measurement 
in all experimentation using excitation/emission wavelengths of 480/580 nm. These 
“free” values were subsequently converted to molar concentrations using calibration 
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curves for doxorubicin to determine the number of loaded or desorbed drug molecules 
per AuNP. Fluorescent measurements were carried out in 96-well plates. For quantitative 
studies, polyethylene glycol was included in the plate well buffer to inhibit non-specific 
sorptive loss of DOX as recently reported on by our group (Curry et al., 2015). In all 
experimentation, doxorubicin fluorescence (excitation/emission: 480/580 nm) and AuNP 
UV-Vis absorbance was quantified using a TECAN infinite M10000 PRO micro-plate 
reader.  
3.3.3 Adsorption Kinetics and AuNP Aggregation 
In order to study the kinetics of DOX adsorption onto the nanoparticle surface, 
fluorescence of a DOX sample (90 μL) was measured for six minutes before the addition 
of AuNP (10 μL, ~10 nM or ~30 nM).  To study the effect of DOX on AuNP 
aggregation, DOX solutions of various concentrations were added to wells containing a 
constant volume of AuNP (10 nM) before recording the absorbance spectra.  
3.3.4 DOX Adsorption Isotherm  
For all adsorption studies, equal volumes of DOX solution (dissolved in nanopure 
H2O with different concentrations) and gold nanoparticles were used to ensure uniform 
surface coverage (Darby and Le Ru, 2014). Typically, the DOX and AuNP solutions 
were mixed in 1.5 mL microcentrifuge tubes and centrifuged at 12,700 rpm for 4 minutes 
to form DOX-AuNP conjugate precipitates. Thereafter, 20 μL of the supernatant solution 
(containing “free” DOX) was carefully transferred to plate wells each containing 80 μL 
of HEPES-PEG 20K buffer solution (final PEG 20K concentration: ~50 mM, final 
HEPES concentration: 4-80 mM, where 80 mM HEPES buffer was used to maintain the 
 43 
sample pH to avoid pH dependent fluorescence variation). To test the effect of pH on 
adsorption, 3 μL of pH citrate buffer (0.3 M, various pH values) was added to DOX 
solutions prior to mixing with the AuNP solution. To evaluate the effect of salt on 
adsorption, NaCl (up to 5 μL) was added to the DOX solution prior to mixing with the 
AuNP solution. In these studies, AuNPs were first rinsed with Nanopure water to remove 
residual salt during AuNP synthesis. This step helped to prevent AuNP aggregation due 
to solvent-salt synergistic effects (Han et al., 2011). For EDTA effect on DOX 
adsorption, EDTA (2 μL, 100 μM) was added to AuNP (25 μL, 13 nM) prior to the 
addition of DOX (25 μL, 4 μM). Adsorbed DOX was calculated using DOX fluorescence 
in the supernatant. The calibration was performed using freshly prepared DOX standard 
solutions with the HEPES-PEG buffer.  
3.3.5 Adsorption of DOX Analogs 
To study the adsorption kinetics of DOX analogs onto AuNPs, fluorescence 
kinetic measurements were conducted. Briefly, 88 µL of HEPES buffer (5 mM, pH 7.6) 
was added to a 96-well plate followed by 2 µL of stock analog solution in EtOH. 
Fluorescence measurements were recorded every 30 sec, and after 150 sec, 10 µL of 
AuNP (10 nM) was added and gently mixed into the wells using a pipette. Nanopure 
water rather than AuNP was added to the control wells. All data were normalized to 
100% fluorescence representing the initial fluorescence intensity measured in each well 
prior to the addition of AuNP. Fluorescence spectra were measured using the following 
excitation/emission wavelengths (nm): DOX: 480/580, DOX-M: 490/586, DeoxyDOX: 
490/576, Anthracene: 252/376. 
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3.3.6 Desorption Studies 
To evaluate the effects of pH, temperature, salt, and solvent concentrations on 
DOX desorption, drug-nanoparticle conjugates were prepared in equal volumes (as 
mentioned previously). In desorption studies, a drug-to-nanoparticle concentration ratio 
of ~300:1 was used to ensure ~100% adsorption of DOX onto AuNP (as evidenced by the 
near total quenching of DOX at this ratio). After mixing AuNP and DOX (both prepared 
in nanopure water without buffer) in 1.5 mL tubes, the conjugate samples were treated 
with pH buffer (2 μL, 0.35 M, various pH values), solvent (ethanol, methanol, 25 μL), or 
temperature (15 min exposure). For the temperature effect studies, high temperature 
samples were submerged in a water bath with water temperature monitored using a 
thermocouple. Samples treated at 4°C and 25°C were achieved by keeping conjugate 
solutions in a refrigerator (4°C) or bench top (room temperature:~ 25°C) for 15 min, 
respectively. For MgCl2 –ethanol desorption studies, AuNP were rinsed prior to treatment 
to decrease previously mentioned solvent-salt synergistic effects. Conjugate samples 
were again centrifuged at 12,700 RPM to form AuNP precipitates and resultant 
supernatant samples were analyzed for DOX concentration as outlined above. To study 
the displacement of DOX from AuNPs by anthracene, increasing concentrations of 
aqueous anthracene solutions were added to wells containing DOX-AuNP conjugates 
with equivalent volumes of nanopure water used in control groups. DOX-AuNP 
conjugate fluorescence measurements were taken for several min prior to the addition of 
anthracene. For both GSH and BSA-induced DOX desorption studies, DOX and AuNP 
were mixed in 96-well plates prior to fluorescence measurements. Different 
concentrations of GSH and BSA solutions were then added to plate wells and mixed by 
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pipetting before subsequent fluorescent measurements at excitation/emission: 480/580 
nm. 
3.3.7 Citrate Assay 
DOX-AuNP conjugate mixtures (1153:1 drug-to-nanoparticle molar concentration 
ratio) and AuNP controls were prepared as outlined above. The mixtures were 
centrifuged and the citrate concentration in the resulting supernatant solution was 
quantified using a citrate assay kit as per manufacturer’s directions (Sigma Aldrich, 
Catalog Number: MAK057). Following an enzymatic reaction, the concentration of free 
citrate in solution correlated to the production of a fluorescent marker dye. The resultant 
citrate concentrations in the supernatant solutions were calculated by comparing the 
sample fluorescence to fluorescence values obtained from known citrate standard 
solutions provided in the kit. 
3.3.8 Infrared Spectroscopy 
Fourier Transform Infrared Absorption Spectra were obtained by a Thermo 
Nicolet 6700 FT-IR Spectrometer. DOX-AuNP conjugate mixtures (1538:1 concentration 
ratio) and AuNP mixtures were prepared in microcentrifuge tubes (n=12). Following 
repeated centrifugation and rinsing steps, precipitate solutions were combined and 
allowed to dry in light-protected weigh boats for 48 h. Subsequently, 150 mg of KBr was 
added to each of the samples before being pressed into round pellets and dehydrated. The 
samples were analyzed using the infrared spectrometer (samples measured against KBr, 
256 scans per sample, 4 cm
-1 
resolution). Spectra baselines were corrected using OMNIC 
software. 
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3.3.9 X-Ray Photoelectron Spectroscopy 
Silicon substrates were sonicated in acetone for 10 minutes prior to drying. For 
AuNP samples, AuNP were concentrated via centrifugation and directly dropped onto the 
surface of the silicon substrate. For DOX-AuNP sample, AuNP were mixed with aqueous 
DOX and concentrated via centrifugation. To maximize the amount of sample recovered, 
DOX-AuNP conjugates were briefly sonicated to remove adsorbed conjugates from the 
microcentrifuge tube surface before being directly dropped onto the silicon substrate. 
Prior to analysis, samples were allowed to dry in a fume hood overnight. XPS analyses 
were performed using a Thermo-VG Scientific ESCALab 250 Microprobe equipped with 
a monochromatic Al Ka X-Ray source (1486.6 eV). All spectra were processed and 
analyzed using CasaXPS software. 
3.3.10 Transmission Electron Spectroscopy 
TEM micrographs were obtained using a Phillips CM30 microscope operated 
with an accelerating voltage of 250 kV. As-prepared AuNP and DOX-AuNP conjugate 
solutions were dropped onto lacey carbon-coated TEM grids and imaged at various 
magnifications.  
3.3.11 Theoretical Investigations 
To thoroughly understand interactions between DOX and AuNP observed 
empirically, we modeled molecular dynamics (MD) varying influences of functional 
groups under experimental conditions. The DOX pdb file was obtained from the Drug 
Data Bank and the hydrogens were added using MarvinSketch software (version 
15.6.29.0, 2015, ChemAxon (http://www.chemaxon.com)). The AuNP pdb file was made 
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with OpenMD nanoparticle builder with forcefield SuttonChen along the lattice constant 
of gold, 4.08 Ả. The AuNP pdb and DOX pdb were imported into MarvinSketch and 
merged into one system. The modelling was made using MOPAC2012 at PM7 level of 
theory (Maia et al., 2012). The visualization and analysis of quantum calculations were 
made using Gabedit (Allouche, 2011). The obtained geometry optimization output file 
was used for 10 ns molecular dynamic (MD) modelling of the ground state geometry with 
universal forcefield (UFF) (Rappe et al., 1992). MarvinSketch was used for drawing, 
displaying and characterizing chemical structures, substructures and reactions. 
3.4 Results and Discussion 
3.4.1 Adsorption of DOX on AuNPs 
The adsorption of DOX on AuNP surfaces was studied by fluorescence 
measurement, where AuNPs serve as an excellent quencher of the fluorescence signal of 
DOX upon adsorption via nanoparticle surface energy transfer (NSET). Isotherm data in 
Figure 3.2A depicts a Langmuir adsorption behavior with maximum DOX loading of ~ 
550 drug molecules per AuNP (citrate capped, ~13 nm  in diameter), indicating 
monolayer adsorption of  DOX on the AuNP surface (Zhang et al., 2012c). The 
adsorption process was complete in less than 30 seconds (Figure 3.2B), suggestive of 
diffusion-limited kinetics.  
Meanwhile, DOX adsorption was accompanied by an aggregation of AuNPs, 
characterized by color change of the AuNP solution from wine red to purple, as shown in 
the red-shifted absorbance spectra (Figure B.1) and TEM images of DOX-AuNP 
conjugates (Figures B.2-4). One explanation may be that when DOX adsorbs onto the
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Figure 3.2 (A) DOX–AuNP isotherm including Langmuir Fit (solid line). See Fig. S7A† for original data with standard errors. (B) DOX 
fluorescence decrease upon addition of AuNP.
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surface of the AuNPs, the negatively charged citrate anions, originally adsorbed on AuNP 
surfaces and providing electrostatic stabilization, are replaced by DOX. Such replacement 
may destabilize AuNPs in solution by decreasing repulsive forces, resulting in AuNP 
aggregation due to gold’s high density and strong van der Waals forces between particles 
in solution (Doane and Burda, 2013). Another mechanism may be due to salt-bridging of 
the negatively charged citrate-coated AuNPs by DOX via its amine group, which is 
positively charged under neutral pH regimes. To verify these hypotheses, we monitored 
the displacement of citrate from AuNP surface by DOX using fluorescence spectroscopy. 
The results indicated that ~ 505 citrate ions were replaced by DOX molecules from each 
AuNP surface (Figure B.5). Considering the size and charge of citrate and the surface 
area of each AuNP, most of the adsorbed citrate molecules were replaced by DOX 
molecules. Despite the persistent existence of citrate on the surface of AuNPs, as pointed 
out by J. Park et al. (Park and Shumaker-Parry, 2015), essentially most DOX molecules 
were adsorbed directly on AuNP surfaces, discrediting the salt-bridge mechanism.  
The replacement of citrate by DOX (Figure 3.3) was further supported by the 
results obtained with Fourier Transform Infrared Spectroscopy (FTIR). Spectral analysis 
of the DOX-AuNP conjugates and citrate-AuNP reveals the existence of much more free 
citrate (a pronounced peak at 1394 cm
-1
) in the DOX-AuNP samples than in the citrate-
AuNP sample (Figure B.6) (Park and Shumaker-Parry, 2014) In addition, the adsorption 
of DOX on AuNP surfaces was distinctive, as evidenced by a larger peak at 1589 cm
-1
, 
assigned to the C=O bond at the 13-keto position of DOX (Barick et al., 2010). 
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Figure 3.3 Citrate displacement from AuNP surface upon addition of DOX. 
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A further question is to identify the driving force underlying DOX adsorption. We 
assume that electrostatic attraction (between the citrate anions on AuNPs and the 
positively charged amine group in DOX) may drive the DOX to approach AuNP 
surfaces, thus facilitating their adsorption even though the DOX-AuNP interaction itself 
was not based on a salt-bridging mechanism (Zhang et al., 2012a; Zhang et al., 2012b, c). 
To evaluate this hypothesis, we studied the effect of NaCl concentrations and solution pH 
on DOX adsorption. When adding DOX solution spiked with various NaCl 
concentrations into the AuNP solution (volume ratio 1:1 which is critical to ensure fast 
mixing and even DOX adsorption onto each AuNP), the results indicated no decrease in 
DOX adsorption capacity even with 136 mM NaCl in the solution (Figure 3.4A), 
suggesting high Na
+
 concentrations did not interfere with DOX adsorption, confirming 
adsorption was not driven by electrostatic attraction (Darby and Le Ru, 2014). 
 
Figure 3.4 Adsorption of DOX onto AuNP in presence of varying NaCl concentrations 
(A) and pH environments (B). 
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As shown in Figure 3.4B, similar results were observed with pH influences. Lower pH 
values (e.g., pH 3) promote complete protonation of DOX, decreasing DOX adsorption 
slightly (< 10%), while providing further evidence against the salt-bridging electrostatic 
mechanism. These findings were further confirmed with the results of desorption 
experiments, where the increase in DOX fluorescence signal due to dissociation of DOX-
AuNP conjugates was monitored under various pH conditions. Herein, low pH 
environments facilitated more desorption (~10%) than alkaline environments (Figure 
3.5A). Since adjusting pH is an effective means to alter the charge states of the species 
involved, again, our results disfavor the electrostatic attraction-based adsorption theory. 
Instead, the pH effect could be explained if DOX adsorption was driven by hydrophobic 
forces, where at lower pH, DOX molecules were completely ionized and displayed less 
hydrophobicity, resulting in lower adsorption and higher desorption, similar to the effect 
of pH on DOX adsorption onto carbon nanotubes (Liu et al., 2007). 
As shown in Figure 3.5B, when using solvents with decreasing polarity (pure 
water, 33% methanol, and ethanol aqueous solutions), more DOX molecules were 
desorbed from AuNP surfaces to the solvent, suggesting DOX hydrophobic functional 
groups are involved in the interaction with AuNPs, consistent with the pH effect. Next, 
DOX-AuNP conjugates were subject to increasing temperatures, which enhanced DOX 
desorption from AuNP surface (Figure 3.5C).  These results suggest desorption of DOX 
from AuNP surfaces is an endothermic process; conversely, adsorption is exothermic and 
spontaneous in nature, consistent with previous work on anthracene and benzene 
adsorption onto AuNP surfaces (Kumar et al., 2002). All experimental results indicate 
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Figure 3.5 DOX desorption from AuNP in presence of varying pH (A), solvent (B) and thermal (C) conditions. 
(D) DOX desorption from AuNP upon addition of competitive molecules ([Glu], [urea] = 45 mM, [GSH] = 182 
μM. 
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DOX adsorption was not driven by electrostatic interaction, but rather by hydrophobic forces. 
3.4.2 Identification of the molecular functionalities contributing to DOX AuNP 
interaction 
To identify which DOX functional groups contribute to its adsorption, we studied the 
interaction between AuNP and compounds sharing structural similarities to DOX (Figure 
3.6). These analogs include anthracene (ANT), 7-deoxy doxorubicin aglycone (DDA), D-
glucose (Glu), Urea, decanoic acid modified DOX (DOX-M) and glutathione (GSH), a 
thiolated compound, for comparison. The results showed that even high concentrations (45 
mM, ~10,000 times DOX concentration) of glucose and urea were unable to displace DOX 
from AuNP surfaces (Figure 3.5D), while comparable levels (µM level) of anthracene could 
replace DOX (Figure 3.7A). Adsorption kinetics experiments further confirmed ANT, DDA, 
and DOX-M all adsorbed on AuNPs (Figure 3.7B) with even higher affinities for AuNP 
surfaces than possessed by DOX. This clearly demonstrates the amine group does not 
contribute to DOX-AuNP interactions, which is in agreement with the characterization of 
DOX-AuNP conjugates with x-ray photoelectron spectroscopy (XPS).  
As illustrated in Figure B.8, N 1s and C 1s XPS spectra for DOX-AuNP clearly show 
binding energy peaks at 402.11, 400.08 eV (Figure B.8A), and 285.40 eV (Figure B.8B) in 
the de-convoluted peaks, attributable to the free amine and C-N groups of DOX, but not Au-
N coordination, as it is well established that the binding energy of N 1s decreases by 1-3 eV 
upon binding to metallic surfaces due to a transfer of electron density from nitrogen to metals 
(Li et al., 2004; Mondal et al., 2015). Taken together, we reason that 
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Figure 3.6 Chemical compounds used in this work mimicking potential DOX functional groups of interest in AuNP adsorption. 
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DOX adsorption onto AuNP surfaces is via the anthracene ring due to cation-π- 
interactions with the adsorbed Au
+
 on AuNP surfaces, similar to previous studies on the 
adsorption of benzene and anthracene onto AuNP surfaces (Kumar et al., 2002; Pagliai et 
al., 2012). MgCl2 induced desorption (Figure B.7B) further strengthened this hypothesis 
since Mg
2+
 ions may create cationic competition for DOX. Although desorption is not 
highly pronounced, the result is reasonable since it is the hydrophobic force rather than 
cation-π- interaction that drives DOX  to the AuNP surface.  
 
Figure 3.7 (A) Fluorescence intensity of DOX from DOX–AuNP conjugates upon addition of 
anthracene. (B) Fluorescence intensity of compounds structurally analogous or with relevant 
functional groups to DOX molecules upon addition of AuNP. 
In addition, ethylenediaminetetraacetic acid (EDTA) was shown to inhibit DOX 
adsorption onto AuNPs (Figure B.7C), presumably due to the coordination of Au
+
 ions 
by EDTA, leaving less Au
+
 available for DOX to interact with. The use of EDTA in this 
context comes with limitations related to charge repulsion. The negative charge 
associated with EDTA makes it difficult for coordination with Au
+
 due to the negative 
citrate layer on AuNP. Nevertheless, the results of the MgCl2 and EDTA experiments 
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support the cation-π- interaction theory. This hypothesis was further substantiated with 
modelling work. 
3.4.3 Modelling of the DOX-AuNP Interaction 
Theoretical models describing the interaction between AuNPs (assumed 0.5 nm in 
size to be relatively efficient with quantum mechanics modelling) and DOX were 
produced (Figure 3.8). The 0.5-nm AuNPs might underestimate the magnitude of the 
forces that govern the interaction between DOX and 13-nm AuNPs, but would not 
change the physiochemical nature of the interactions. DOX has 3 carbonyl groups in 
positions 7, 9 and 10 (Figure 3.8A) which contribute to the stabilization of the molecular 
conformation through formation of hydrogen bonds with nearby hydroxyl groups (e.g., at 
positions 9 and 42 as well as 10 and 43). The steric hindrance of C30 may favor hydrogen 
bonding between 7 and 44, or 7 and 40. Disruption of the proposed hydrogen bonds may 
increase the ionization potential of DOX, facilitating DOX adsorption to AuNPs (Figure 
3.9B). An earlier study reported DOX interactions with nanoscale particles is mainly due 
to van der Waals forces forming a S-conformation DOX layer on the particle surface 
(meaning the ring structures are directly interacting with the chitosan particle),(Shan et 
al., 2014) which is generally consistent with our isotherm data (Figure 3.2A). However, 
functional groups driving the absorption of DOX were not definitively identified, and 
may differ when interacting with AuNPs from that with chitosan. To address these issues, 
we performed quantum molecular dynamics modelling to reveal the detailed mechanism 
of DOX-AuNP interaction (Figure B.9). 
First, we calculated and compared the IR frequencies of DOX (with and without 
AuNPs) to explain the peak shift observed in FTIR spectra. Without AuNPs, the 
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stretching vibrational frequency of the carbonyl group of DOX is temperature 
independent between 200 - 400 °K (Figure 3.9A and B). In the presence of AuNPs, the 
carbonyl stretch peak shifted to a higher frequency (Figure 3.9C). In addition to this up-
field frequency shift, the peak of the carbonyl stretch splits due to the different carbonyl 
functionalities, in other words, the carbonyls on the ring and on the ketone may interact 
with AuNPs differently. Further, the intensity of the carbonyl stretch in ketones decreased 
drastically, indicating the carbonyl groups (positions 7, 9 and 10 in Figure 3.8A) are 
involved in DOX-AuNPs interactions. Similarly, the shift of frequency-fingerprint of the 
C=C of the anthracene ring (~1600 cm
-1
) demonstrates the involvement of the ring 
structure in the AuNP-DOX interaction (highlighted region in Figure 3.9). In contrast, the 
possibility of binding between the DOX amine group and AuNP via Au-N bonds is low, 
as evidenced by the low peak intensity of 386 cm
-1
, the frequency of Au-N bond 
stretching.  
To further identify the contribution of each DOX functional group to its 
adsorption onto AuNP, molecular dynamics (MD) and quantum mechanics (QM) were 
employed to model the ground state conformations of the DOX-AuNP system. We 
constructed three models to differentiate the contribution of the amine group in the sugar 
ring from that of the anthracene ring. In model 1, we compared the binding of DOX 
molecules with that of their analogue lacking the amine group. The model demonstrated 
an 8.3% probability that ring 5 (the sugar ring containing the amine group) bends toward 
AuNP surfaces, potentially forming an Au-N bond. However, this bending phenomena 
was persistent with the DOX analog lacking the amine group in ring 5, suggesting the 
bending of DOX is not due to the formation of an Au-N bond, but likely attributable to 
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Figure 3.8 (A) Structure of doxorubicin and (B) Doxorubicin with gold nanoparticles. 
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Figure 3.9 The IR spectrum showing the peak shifts in DOX in ground state at room temperature (A), excited 
state with increased temperature (B) and DOX–AuNP conjugates (C). Features are labelled in the figure. 
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π - σ attraction (where the σ bonds were from ring 5) that dominated the edge to face 
interaction (Hunter and Sanders, 1990).  
In model 2, we evaluated the contribution from ring 5 and the carbonyl groups in 
ring 2 by applying a DOX analog lacking ring 5 to the AuNP (Figure B.10A); the results 
demonstrated electrostatic interaction between the carbonyl of ring 2 and the AuNP 
surface. Next we modelled how AuNPs interact with anthracene, a DOX analog with 
only the rings 1-3 (model 3). In this model, DOX interacted with AuNPs by cation - π 
interactions (Figure B.11) between the Au
+
 cations adsorbed on the AuNP surface, and 
anthracene rings 1 and 3. The AuNP–anthracene interaction appeared with low 
frequencies (< 400 cm
-1
) and involved the puckering of the ring observed through the 
peak at ~680 cm
-1
(Figure B.10B), where the =C-H bending appeared.  
The DOX analog without ring 5 adsorbed on AuNP surface showed low carbonyl 
group stretching frequencies (Figure B.10A), attributable to the direct anchoring of the 
two carbonyl groups (located on ring 2) to the AuNP surface. The carbonyl-Au 
coordination facilitates the cation - π interaction of rings 1 and 3 on the AuNP surface, 
synergistically contributing to the overall force of the DOX–AuNP interaction. 
Combining the experimental work and theoretical modelling, we conclude the 
main forces that contribute to DOX adsorption onto AuNPs consist of π-cation 
interactions and Au-carbonyl coordination chemistry (Figure 3.10C). Nevertheless, it is 
reasonable to expect contributions from intermolecular forces such as electrostatic 
attraction between DOX and residual citrate molecules (Figure 3.10A) and hydrogen 
bonding between several DOX molecules (Figure 3.10B). Considering the DOX 
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Figure 3.10 (A) Electrostatic interaction (+-) and hydrogen bonding (––) between adsorbed citrate 
and adsorbed DOX molecules on AuNP surfaces. (B) Hydrogen bonding between adsorbed DOX 
molecules on AuNP surface. (C) Cation–π and coordination chemistry between DOX and AuNP. 
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adsorption with intermolecular interactions, the adsorbed DOX and a small number of 
residual citrate molecules form an assembled monolayer structure, impairing the charge-
based stabilization of AuNPs due to decreased net surface charge relative to the original 
citrate-capped AuNPs. 
 
 
To examine the strength of the DOX-AuNP interaction, we evaluated DOX 
desorption in the presence of bovine serum albumin (BSA) and GSH, both of which are 
present in high concentration in blood and cytoplasm. BSA adsorbs on citrate-AuNPs 
through a mixed mechanism involving electrostatic, hydrophobic, and coordination 
chemistry while GSH adsorbs to AuNPs via thiol-gold bonds (Brewer et al., 2005; Gao et 
al., 2012). Our results demonstrate GSH could displace DOX rapidly and efficiently 
(~70% replacement over 60 min), demonstrating that the thiol-gold bond is stronger than 
the forces governing DOX-AuNPs interactions (Figure 3.11B, Figure 3.5D). BSA also 
facilitated DOX desorption, although not as efficiently as GSH with ~ 18% DOX 
desorbed in the presence of ~0.7 mM BSA over 50 min (Figure 3.11A). Such DOX 
Figure 3.11 BSA (A) and GSH (B) induced DOX fluorescence signal increase via desorption from 
AuNP surface. 
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displacement by common blood-borne constituents are significant for in vivo drug 
delivery research, since the concentrations of GSH (µM level in blood and mM level in 
cytoplasm) and BSA (~ 0.7 mM in blood) used in this study were physiologically 
relevant.  
3.5 Conclusions 
In summary, for the first time, we provide both empirical and theoretical evidence 
demonstrating the mechanism of DOX adsorption onto AuNP is based on cation- π 
interactions and formation of a DOX monolayer on the nanoparticle surface. DOX 
adsorption is proposed as a two-step process where hydrophobic forces first drive DOX 
molecules toward the AuNP surface prior to cation–π interactions and coordination 
chemistry between DOX and the cationic surface of AuNP anchoring DOX to AuNP 
surface and replacing most of the citrate molecules. Contrary to the conventional 
understanding, the contribution of the amine group in DOX to AuNP adsorption is 
negligible, though together with the hydrogen bonding as an intermolecular force, it may 
contribute to the formation of an adlayer on AuNP with residual citrate. Physiologically-
relevant molecules (GSH and BSA) were shown to rapidly desorb DOX from the 
nanoparticle surface at physiological concentrations, an important point to consider for in 
vivo drug delivery and controlled release studies. Despite the simplicity of the DOX-
AuNP interaction for drug loading, the nanoconjugate remains vulnerable to these 
physiological conditions. Stabilization methods such as co-adsorption of DNA or PEG 
should be considered when employing simple DOX-AuNP chemistry. Considering the 
volume of research articles dedicated to DOX-AuNP delivery systems, detailed 
knowledge of the nature of this fundamental interaction may allow researchers to better 
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design delivery systems and estimate therapeutic drug loading and release parameters, 
therefore increasing anticancer drug efficiencies both in vivo and in vitro. 
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Chapter 4 Conclusions 
This thesis furthers the field of nanotechnology by first providing a protocol to 
enhance the accuracy of doxorubicin quantification in drug delivery studies and second 
by investigating the interaction mechanism between doxorubicin and citrate-capped gold 
nanoparticles. Doxorubicin is commonly used as a model drug in cancer studies due to its 
high toxicity towards cancer cells and also due its ease of use in the laboratory. Having 
hydrophilic characteristics makes the drug water soluble and therefore easy to incorporate 
into many nanoscale systems, however, its hydrophobic character allows for non-specific 
interactions with plastic vessels and surfaces. These interactions, over the course of 
several minutes can impact quantification measurements of the drug, routinely completed 
using fluorescence spectroscopy. To solve the problem of non-specific adsorption and the 
erroneous drug loading values that result, we studied the effect of including trace 
amounts of polyethylene glycol in the measurement buffer. High molecular-weight 
polyethylene glycol was witnessed to inhibit non-specific adsorption of doxorubicin to 
plate well surfaces at trace concentrations, allowing for a rapid and simple method to 
accurately quantify the concentration of free drug in solution. 
Gold nanoparticles have received immense research interest in the field of drug 
delivery and targeted cancer therapy. With this in mind, we aimed to shed light on the 
specific nature of the chemical interaction between doxorubicin and citrate-capped gold 
nanoparticles. As with many doxorubicin-nanomaterial interaction theories, the drug was 
conventionally thought to adsorb onto AuNPs mainly through electrostatic bridging 
interactions between the negative citrate capping agent used to synthesis and stabilize the 
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nanoparticles and the positively charged amine group of DOX. Experimental and 
theoretical results were presented in Chapter 2 which carefully uncovers DOX adsorption 
to gold as a rapid, multi-step process whereby hydrophobic forces drive the drug 
molecule to the surface of the nanoparticle before a combination of cation-π and 
coordination chemistry anchor the drug to the gold core.  
In order for nanoscale-drug conjugates to be successful in animal-based models, 
several key features must first be optimized. First, the size of the nanoparticle complex 
must remain “nanoscale” if the delivery vehicle is going to make use of the EPR effect. 
To this point, the nanoparticle must be stable in the high ionic strength environments 
present in in vivo systems. Secondly, the drug must be anchored to the nanoparticle in a 
way that allows for controlled release at the target site. The simple adsorption of DOX 
onto citrate-capped gold nanoparticles provides issues with respect to size, stability and 
controlled release. Upon adsorption of high concentrations of DOX, AuNP aggregate 
irreversibly, signifying their instability. Additionally, the aggregated complexes lose their 
nanoscale character by clustering into large and non-uniform complexes. Despite these 
facts, much research activity is still devoted to a drug delivery platform utilizing both 
DOX and gold based-nanomaterials.  
Recent advances such as the adsorption of DOX onto and into hollow gold 
nanoparticles have allowed for promising in vivo demonstrations. Still, as shown in 
Chapter 3, interactions relying solely on the simple adsorption chemistry described here 
provide problems related to controllable release of the therapeutic cargo. Small molecules 
such as GSH have been show to rapidly desorb DOX from the nanoparticle surface; 
considering the high concentrations of GSH and other thiolated compounds in the body,
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Figure 4.1 Effect of reagent addition order on DOX adsorption and DOX-AuNP stability. 
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Figure 4.2 Effect of PEG polymer length on DOX adsorption and DOX-AuNP stability. 
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the controllable release at specific and targeted sites of interest, a major selling point for 
nanoscale drug delivery vehicles, becomes more difficult. 
With these considerations in mind, several recommendations for future work may 
be made moving forward. First, if the simple DOX-AuNP interaction is to become 
successful in clinical settings, the problems associated with controlled release and 
nanoparticle aggregation must be solved. Previously mentioned work using hollow gold 
nanoparticles have touched on this through use of thiolated PEG and a stabilizing agent in 
photothermal-chemotherapy. Further investigations on thiolated PEG-AuNP vehicles for 
DOX delivery may prove useful. Systematic research investigating the effect of reagent 
addition order (Figure 4.1) and PEG polymer length (Figure 4.2) may allow for advances 
with respect to the extent to which controllable release is achievable. 
Finally, the inclusion of nanoscale gold into a combinatory therapeutic approach 
to cancer may also prove beneficial from a clinical point of view. The advent of 
promising gold-based nanomaterials, such as biodegradable gold liposomes, may present 
an opportunity to include DOX into novel nano-systems, considering the ubiquitous 
nature of liposomal doxorubicin in cancer treatment today. Additionally, such innovative 
investigations may pave the way for researchers to translate combinational chemo, radio 
and photothermal therapies from the bench to the bedside. 
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Appendix A Supporting Information For Chapter 2 
 
Figure A.1 The effect of PEG 4K and PEG 8K (various concentrations) on DOX adsorption to plate-well 
surfaces. In control wells, no chemicals other than DOX aqueous solution were added. 
 
 
Figure A.2 Comparison of DOX adsorption onto AuNP in the presence and absence of 10 ppm PEG 
20K. AuNP-DOX conjugates were dissolved with 2 uL of 1 M KCN solution into 100 uL of AuNP-DOX 
solution with released DOX quantified by fluorescence. The data demonstrate no significant impact of 
PEG 20K on DOX loading to AuNP (p=0.065; one-way ANOVA). 
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Figure A.3 Optical absorbance of 1% PEG 20K in 5 mM HEPES buffer. 
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Appendix B Supporting Information for Chapter 3 
 
 
 
Figure B.1 AuNP absorbance spectra upon addition of increasing [DOX] (Inset: AuNP color 
change upon addition of DOX, DOX:AuNP molar concentration ratio from right to left: 0, 385, 
769, 1538). 
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Figure B.2 TEM micrograph of ~13 nm citrate-capped AuNP used in this work using TEM (above) and 
HR-TEM (bottom). (Scale bars included in figures). 
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Figure B.3 TEM micrograph of DOX-AuNP conjugates. DOX:AuNP molar concentration ratio = 307:1 
(Scale bar: 20 nm). 
 
 
Figure B.4 TEM micrograph of DOX-AuNP conjugates. DOX:AuNP molar concentration ratio = 307:1 
(Scale bar: 200 nm). 
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Figure B.5 Citrate displaced per AuNP quantified via DOX fluorescence signal measured in supernatant 
solution (p<0.5). 
 
 
Figure B.6 FTIR spectra of DOX-AuNP conjugate and AuNP. 
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Figure B.7 (A) Original DOX-AuNP loading isotherm including standard error bars. (B) Desorption of 
DOX from AuNP surface after treatment with MgCl2 ([62.5 mM]), EtOH (31.25% v/v) and EtOH-
MgCl2. DOX:AuNP ratio = 317:1. (C) Adsorption of DOX to AuNP surface after EDTA ([3.84 µM]) 
treatment of AuNP. DOX:AuNP ratio = 308:1.
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Figure B.8 XPS N 1s (A) and C 1s (B) deconvoluted spectra for DOX-AuNP conjugate solutions.
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Figure B.9 Molecular orbital (MO) of DOX showing localized electron sites in (A) first excited and (B) 
ground states. The first excited state is sampled between 200 - 400 °K at the PM7 level of theory in 
MOPAC2012 with PCM water. The first 6 energy level state of the alpha orbital are displayed. The 
ground state MO of the HOMO is located at the first benzene ring, which is the highly hydrophobic 
region of DOX. In contrast, the MO of LUMO is delocalized around the hydrophobic site of DOX. At 
HUMO 1, the -OH group is involved in MO while in HUMO 4 the carbonyl contributed to the 
delocalization of the MO. In LUMO 1, the MO was delocalized from the ring 4 containing -OH to the 
ring 1. However, LUMO 4 MO does not involve a hydrophobic electronic site. This suggests a possible 
transition that involves either the carbonyl or the hydroxyl functional group. Regarding the particular 
transition of HOMO 1 to LUMO 1, the MO migrated from -OH site to C=O site. Moreover, the 
delocalisation of the MO of the hydrophobic site (ring 30) to the acceptor hydrophobic site at the rings 1 
and 2. However, HOMO 4 showed a migration of MO from hydrophobic electronic transition to a 
localized highly electrophilic site. The HOMO 5 displayed the MO delocalised around the hydrophobic 
electronic sites in ring 1, 2 and 3 towards HOMO 5 localized electrophilic site. The main observation was 
the absence of MO in ring 5 ground state HOMO to LUMO 5. The thermochemistry calculation 
demonstrated the contribution of the ring 5 (ether) in the electronic transition is an intra-thermochemistry 
reaction that involved the amine functional group. As for the ground state, the hydrophobic electronic 
transitions are partially delocalized. 
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Figure B.10 (A) Modelling of IR spectrum of DOX without ring 1 connected to amine moiety with a 0.5 
nm AuNP. (B) Modelling of IR spectrum of the DOX-like anthracene with 0.5 nm AuNP. 
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Figure B- 1.  
 
Figure B.11 Calculation of electrostatic potential of the surface at PM7 level of theory: (A) DOX-
like anthracene-AuNP, and (B) DOX without ring 1-AuNP. The potential energy surface of the last 
1 ns of 12 ns MD demonstrated DOX bent and formed an Au-N bond (Model 1). Further QM 
calculation of DOX alone with high level of theory in gas phase as well as with continuum water 
(B3LYP/6-31G(d)) had depicted a bent formation. Increasing the theory level did not change the 
bend. This highlights the hypothesis that the bent formation between ring 5 containing N and the 
ring 1 to 4 may be due to the π - σ attraction that dominated the edge to face interaction (Hunter 
and Sanders, 1990). Therefore, the bending of ring 5 is likely to be independent of the presence of 
AuNP. To refine the interaction mechanism between DOX – AuNP, we further analyzed two 
models, model 2 was DOX lacking ring 5, which provided insight of the carbonyl interaction with 
the AuNP surface. 
